HIKAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 298.6 INR | -1.47% |
|
-1.19% | -1.78% |
| Sales 2024 * | 18.08B 217M | Sales 2025 * | 20.78B 249M | Capitalization | 36.83B 442M |
|---|---|---|---|---|---|
| Net income 2024 * | 682M 8.18M | Net income 2025 * | 1.03B 12.37M | EV / Sales 2024 * | 2.04 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 * |
54.3
x | P/E ratio 2025 * |
35.6
x | Employees | - |
| Yield 2024 * |
0.2% | Yield 2025 * |
0.2% | Free-Float | 30.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hikal Limited
| 1 day | -1.47% | ||
| 1 week | -1.19% | ||
| Current month | +12.64% | ||
| 1 month | +10.92% | ||
| 3 months | +1.69% | ||
| 6 months | +3.97% | ||
| Current year | -1.78% |
1 week
287.20
314.50
1 month
262.40314.50
Current year
260.30314.50
1 year
250.10329.00
3 years
194.90742.00
5 years
56.90742.00
10 years
56.90742.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 95-12-31 | |
Jai Hiremath
FOU | Founder | 76 | 88-07-07 |
Kuldeep Jain
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jai Hiremath
FOU | Founder | 76 | 88-07-07 |
| Chief Executive Officer | 50 | 95-12-31 | |
| Director/Board Member | 72 | 92-02-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 298.6 | -1.47% | 239,703 |
| 24-04-18 | 303 | +0.71% | 901,460 |
| 24-04-16 | 300.8 | +0.03% | 118,599 |
| 24-04-15 | 300.8 | -0.46% | 361,802 |
| 24-04-12 | 302.2 | +0.18% | 176,396 |
Delayed Quote NSE India S.E., April 19, 2024 at 07:43 am EDT
More quotes
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
298.7
INR
Average target price
330
INR
Spread / Average Target
+10.48%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.16% | 197B | |
| -9.69% | 147B |
- Stock Market
- Equities
- HIKAL Stock
- HIKAL Stock
